Purpose of the development: Drugs designed to neutralize the effect of antibodies and have immunomodulatory effect acting on the various links in the human immune system and increases nonspecific resistance.

Recommended application field: Medicine.

Advantages over analogues: Highly effective medicines.

The development stage readiness: Introduced in production

Description of the development:
()
Drugs acting basis immunoglobulins containing an increased amount of specific IgG. Human immunoglobulin against herpes simplex virus type 1 (IMMUNOGLOBULINUM HUMANUM CONTRA HERPES VIRUS SIMPLEX TYPUS 1) • drug for the treatment of diseases caused by the herpes simplex virus type 1 , including encephalitis , encephalomyelitis , meningoencephalitis arahnoentsefalita , arachnoiditis , entsefalopoliradokulitov etc. Human immunoglobulin against herpes simplex virus type 2 (IMMUNOGLOBULINUM HUMANUM CONTRA HERPES VIRUS SIMPLEX TYPUS 2) • drug for the treatment of various clinical manifestations of diseases caused by the herpes simplex virus type 2 , namely primary and recurrent urogenital infections in men and women , genital herpes infection pregnant women and related obstetric pathology . ZOSTEVIR ( immunoglobulin VARICELLA ZOSTER VIRUS HUMAN LIQUID ) (ZOSTEVIR) • drug used to treat herpes infection of patients with lesions of the nervous system caused by the virus Varicella Zoster. Human immunoglobulin antitsitomegalovirusny (IMMUNOGLOBULINUM HUMANUM ANTICYTOMEGALOVIRUS) • drug for the treatment of various clinical manifestations of CMV infection in adults and children , in particular: cytomegalovirus infection in pregnant women with complicated obstetric history to prevent violations of pregnancy ( prevention of threatened miscarriage , placental insufficiency development , fetal death ) CMV - infection in pregnant women with complicated obstetric history to prevent violations of current planned pregnancy ; primary CMV - infection in pregnant women with uncomplicated history to prevent obstetric complications ; CMV - infection in neonates and infants born to infected mothers , and with clinical manifestations of the disease ; CMV - infection with the adult central nervous system . TSITOBIOTEKT ( human immunoglobulin antitsitomegalovirusny LIQUID ) (CYTOBIOTECT) • drug for the treatment of cytomegalovirus infection in immunosuppressed patients , including after transplantation. Therapy of acute cytomegalovirus infection in immunocompromised patients , such as newborns , as well as in patients with drug immunosuppression or immunodeficiency due to other causes ( including AIDS ) . Human immunoglobulins against the virus Epstein -Barr virus (IMMUNOGLOBULIN HUMANUM CONTRA VIRUS EPSTEIN - BARR) • drug for the treatment of infectious mononucleosis and diseases of the central and peripheral nervous system caused by the Epstein - Barr virus , including encephalitis , encephalomyelitis , meningoencephalitis arahnoentsefalita , arachnoiditis , entsefalopoliradikulitov etc. GERPIMUN 6 ( Immunoglobulin against herpes virus type 6 human liquid ) (HERPIMUN 6) • drug used to treat herpes infection of patients with lesions of the nervous system caused by the herpes virus type 6 . Chlamydia human immunoglobulin (IMMUNOGLOBULINUM HUMANUM ANTICHLAMYDICUM) • drug for the treatment of chlamydial infection , including the defeat of urogenital tract , including salpingitis , salpingooforita , vaginitis , urethritis , prostatitis, cystitis , uretroprostatita , miscarriage , infertility and others . Human immunoglobulin AGAINST TOXOPLASMA GONDII (IMMUNOGLOBULINUM HUMANUM SONTRA TOXOPLASMA GONDII) • drug for the treatment of patients with toxoplasmosis in pregnant women and related obstetric pathology , as well as patients with lesions of the urogenital tract against the backdrop of toxoplasmosis.

Information about newness of the development:
there are inventor's certificate -- 1 items

corresponds technical description
Guarantees stable results getting

Possibility of transfer abroad:
Licence's sale
Technological document's sale
Creation of joint enterprise
Realization of finished commodity

Photo

Country Ukraine

For additional information turn to:
E-mail: gal@uintei.kiev.ua